Category Archives: HCP

About Rethymic HCP

HCP – Clinical Trials

The safety and efficacy of RETHYMIC® (allogeneic processed thymus tissue–agdc) was evaluated in 105 patients across 10 clinical trials. The effectiveness of RETHYMIC was evaluated in 95 of those patients with congenital athymia in 10 clinical trials with follow-up of … Continue reading

HCP – Educational Resources

As you discuss the care of your patient with their family or caregiver, you may find these materials and organizations helpful. Medical Literature These articles are provided by Enzyvant for your education and for discussion of FDA-approved use. RETHYMIC® (allogenic … Continue reading

HCP – How to access Treatment

RETHYMIC® (allogeneic processed thymus tissue–agdc) is currently available at one location in Durham, North Carolina. To obtain the contact information for the single site of administration in Durham, North Carolina, please contact Enzyvant Medical Information at +1 833 369 9868 … Continue reading

HCP – After Treatment

How long does it take for RETHYMIC to work? Immune reconstitution sufficient to protect from infection is unlikely to develop prior to 6-12 months after treatment with RETHYMIC5. For some patients elevated naïve T cell numbers are not observed until … Continue reading

HCP – About Us

Learn about the diagnostic pathway for congenital athymia, including how to differentiate it from Severe Combined Immunodeficiency (SCID), and about the different phenotypes of congenital athymia. What is congenital athymia? Congenital athymia is an ultra-rare primary immunodeficiency which is characterized … Continue reading

HCP – Patient Support

Supporting the treatment journey Enzyvant CONNECT is here to provide personalized support throughout your child’s treatment journey with RETHYMIC® (allogeneic processed thymus tissue–agdc). The Enzyvant CONNECT team will assist families with:

Main HCP

A guide about congenital athymia for healthcare providers Congenital athymia is an ultra-rare condition characterized by the absence of a thymus at birth.1 Estimated incidence in the United States is approximately 17 to 24 infants for every 4 million live … Continue reading